<DOC>
	<DOC>NCT00789477</DOC>
	<brief_summary>This is a Phase 2, doubled-masked, randomized study of the efficacy and safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in subjects with diabetic macular edema (DME). Approximately 200 subjects will be randomized in the US, Canada, Australia and EU.</brief_summary>
	<brief_title>DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact</brief_title>
	<detailed_description>Qualified subjects will be randomized to one of 5 treatment arms. The active (treatment) phase of the study will be 52 weeks, with a 6 month safety follow-up</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<criteria>Patients with clinically significant DME with central involvement Adults 18 years or older with type 1 or 2 diabetes mellitus with diabetic macular edema ETDRS BCVA: 20/40 to 20/320 (letter score of 73 to 24) in the study eye History of vitreoretinal surgery in the study eye Panretinal laser photocoagulation or macular laser photocoagulation in the study eye within 3 months of screening Previous use of intraocular or periocular corticosteroids in the study eye within 3 months of screening Previous treatment with antiangiogenic drugs in either eye (pegaptanib sodium, anecortave acetate, bevacizumab, ranibizumab, etc) within 3 months of screening Uncontrolled diabetes mellitus Uncontrolled hypertension defined as systolic &gt; 180mmHg or &gt; 160 mmHg on 2 consecutive measurements or diastolic &gt; 100 mmHg on optimal medical regimen Ocular disorders in the study eye, other than DME, that may confound interpretation of study results</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>